secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001104659-23-002028
Event type: debt
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 1.02, 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia enters up to $100M royalty financing with HealthCare Royalty; repays SVB debt
--------------------------------------------------------------------------------

- HealthCare Royalty provides up to $100M; initial $32.5M closing, $22.3M used to retire SVB term debt.
- Additional $7.5M for PH product acquisition, $35M upon favorable patent litigation outcome, $25M mutual.
- Non-dilutive capital extends cash runway through at least 2024; minimum cash covenant $7.5M in 2024, $15M from 2025.
- HCRx receives tiered royalty (0.36%-10%) on net revenue capped at 175% of funded amount plus IRR true-up.
- Financing supports YUTREPIA launch; litigation with United Therapeutics ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465923002028/0001104659-23-002028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465923002028/tm232655d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-002028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer